Drug intelligence / Profile preview

SER-777

Development stage: Preclinical
Lead developer: Serentrix
Modality: Small Molecules

Overview

SER-777 is a small molecule TRPV1 receptor antagonist being developed by Serentrix for the treatment of uvulitis in horses. TRPV1 (Transient Receptor Potential Vanilloid 1) is a non-selective cation channel that plays a critical role in the detection and integration of painful stimuli and inflammatory processes. A historical challenge in the development of TRPV1 antagonists has been the induction of hyperthermia as a side effect; however, SER-777 is specifically designed to block TRPV1 activity while avoiding these hyperthermic adverse events. The drug is currently in pre-clinical development as part of Serentrix's animal health pipeline.

Targets

TRPV1 (Transient receptor potential cation channel subfamily V member 1)

Beyond the preview

Go deeper on SER-777.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SER-777.

Explore the full profile